Verition Fund Management LLC grew its holdings in McKesson Co. (NYSE:MCK) by 731.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,167 shares of the company’s stock after purchasing an additional 22,139 shares during the period. Verition Fund Management LLC’s holdings in McKesson were worth $3,357,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Boston Partners increased its stake in shares of McKesson by 54.5% during the second quarter. Boston Partners now owns 6,237,042 shares of the company’s stock valued at $832,021,000 after buying an additional 2,200,669 shares during the period. Vulcan Value Partners LLC increased its stake in shares of McKesson by 7.8% during the second quarter. Vulcan Value Partners LLC now owns 3,768,099 shares of the company’s stock valued at $502,664,000 after buying an additional 273,090 shares during the period. Pzena Investment Management LLC increased its stake in shares of McKesson by 7.6% during the second quarter. Pzena Investment Management LLC now owns 2,836,710 shares of the company’s stock valued at $378,417,000 after buying an additional 201,062 shares during the period. Kiltearn Partners LLP increased its stake in shares of McKesson by 6.3% during the first quarter. Kiltearn Partners LLP now owns 1,914,898 shares of the company’s stock valued at $269,350,000 after buying an additional 112,800 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec increased its stake in shares of McKesson by 0.6% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,663,100 shares of the company’s stock valued at $234,281,000 after buying an additional 9,300 shares during the period. Institutional investors and hedge funds own 88.28% of the company’s stock.

MCK opened at $131.78 on Tuesday. McKesson Co. has a 1 year low of $122.49 and a 1 year high of $178.86. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.57 and a current ratio of 1.00. The stock has a market capitalization of $25.68 billion, a price-to-earnings ratio of 10.44, a P/E/G ratio of 1.37 and a beta of 1.25.

McKesson (NYSE:MCK) last posted its earnings results on Thursday, July 26th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.01. McKesson had a positive return on equity of 25.19% and a negative net margin of 0.18%. The company had revenue of $52.61 billion for the quarter, compared to analyst estimates of $52.91 billion. During the same quarter in the previous year, the firm earned $2.47 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. sell-side analysts predict that McKesson Co. will post 13.31 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 1st. Shareholders of record on Tuesday, September 4th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 1.18%. The ex-dividend date of this dividend is Friday, August 31st. This is a positive change from McKesson’s previous quarterly dividend of $0.34. McKesson’s payout ratio is 12.36%.

MCK has been the topic of several research reports. ValuEngine lowered McKesson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. Leerink Swann set a $160.00 price target on McKesson and gave the company a “market perform” rating in a research note on Tuesday, May 29th. Royal Bank of Canada cut their price target on McKesson to $158.00 and set a “market perform” rating on the stock in a research note on Friday, June 29th. Morgan Stanley cut their price target on McKesson from $175.00 to $142.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 3rd. Finally, Standpoint Research upgraded McKesson from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $154.30.

In other McKesson news, Director N Anthony Coles sold 1,350 shares of McKesson stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $128.69, for a total value of $173,731.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.87% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Recommended Story: Using the New Google Finance Tool

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.